<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310295</url>
  </required_header>
  <id_info>
    <org_study_id>12029-2008</org_study_id>
    <nct_id>NCT02310295</nct_id>
  </id_info>
  <brief_title>Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema</brief_title>
  <acronym>IBeTA</acronym>
  <official_title>Bevacizumabe e Acetato de Triancinolona Intra-vítreo Associados à Laserterapia em Pacientes Com Edema Macular diabético (IBeTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To compare the effects of macular photocoagulation with or without intravitreal
      bevacizumab (IVB) or triamcinolone (IVTA) for the treatment of diabetic macular edema (DME).
      Casuistic and Methods: 58 eyes of 44 patients with diffuse DME were randomized to receive
      either IVB + focal/grid laser (IVB-Laser, n=19), IVTA + focal/grid laser (IVTA-Laser, n=16)
      or focal/grid laser alone (Laser, n=23). Ophthalmic evaluation, including best-corrected
      visual acuity (BCVA), intraocular pressure (IOP) and central macular thickness (CMT) were
      performed at baseline and monthly for 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central subfield macular thickness</measure>
    <time_frame>12 months</time_frame>
    <description>retinal thickness measured with optical coherence tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Best corrected visual acuity</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>IVB-Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal Bevacizumab combined with focal laser therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVTA-Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal Triamcinolone combined with focal laser therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>focal laser therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser</intervention_name>
    <description>focal macular laser therapy</description>
    <arm_group_label>IVB-Laser</arm_group_label>
    <arm_group_label>IVTA-Laser</arm_group_label>
    <arm_group_label>Laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Intravitreal injection of Bevacizumab</description>
    <arm_group_label>IVB-Laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>Intravitreal injection of Triamcinolone Acetonide</description>
    <arm_group_label>IVTA-Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. clinically significant diabetic macular edema (DME) with diffuse leakage involving the
             center of the fovea, with DME greater than 275 microns in OCT examination

          2. BCVA between 0.3 LogMAR (logarithm of smaller angle of visual resolution) (20/40) and
             1.6 LogMAR (20/800)

          3. signed of inform Consent.

        Exclusion Criteria:

          1. HbA1c levels greater than 10%

          2. thromboembolic event history (including myocardial infarction and stroke)

          3. vitreo-macular traction on OCT

          4. coagulation disorders

          5. macular ischemia on fluorescein angiography examination

          6. proliferative diabetic retinopathy that required treatment

          7. eye surgery

          8. history of ocular hypertension or glaucoma

          9. any ocular pathology which in the opinion of the investigator, could macular edema or
             change the visual acuity during the study period (for example, retinal vascular
             occlusion, uveitis or other inflammatory eye disease, neovascular glaucoma)

         10. systemic corticosteroid therapy

         11. any conditions that could affect the documentation

         12. any previous treatment for diabetic macular edema.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Andre Messias</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>Macular edema</keyword>
  <keyword>Anti-VEGF</keyword>
  <keyword>Triamcinolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

